Merck/Kyorin Phase III Dual PPAR Agonist On First-In-Class Path For Diabetes

Merck/Kyorin's dual peroxisome proliferator-activated receptor agonist MK-0767, a new antidiabetic in Phase III, appears to be winning the development race for first market entrant in its class